Advertisement
PFE or PRAX or ZTS
Which Stock Would AI Choose? Pfizer (PFE) vs. Praxis Precision Medicines (PRAX) vs. Zoetis (ZTS) Stock Comparison
Key Takeaways
- PFE offers stability with ~$158B market cap, $62.6B TTM revenue, and YTD gains of 13%, driven by oncology and vaccine pipeline progress amid post-COVID adjustments.
- PRAX, a clinical-stage biotech with $7.7B market cap and no revenue, shows explosive 615% 1-year return but recent volatility from FDA filings for CNS therapies like relutrigine.
- ZTS (~$51B market cap, $9.5B 2025 revenue) faces headwinds with 28% 1-year decline due to Librela safety concerns, though livestock strength supports modest 2026 growth outlook.
- PFE leads in scale and dividend appeal; PRAX in momentum; ZTS in animal health niche but with higher near-term risks.
- Relative performance highlights biotech upside in PRAX versus established cash flows in PFE and ZTS.
Introduction
This stock comparison evaluates PFE (Pfizer), a global pharmaceutical leader; PRAX (Praxis Precision Medicines), a clinical-stage CNS-focused biotech; and ZTS (Zoetis), the top animal health company. Traders seeking momentum may eye PRAX's surge, while investors favoring stability might prefer PFE or ZTS's recurring revenues. In the current market, with healthcare sector rotation amid pipeline catalysts and economic pressures, this analysis contrasts business models, recent momentum, and relative positioning to inform stock comparison decisions.
PFE Overview and Recent Performance
Pfizer (PFE), a biopharmaceutical giant with ~$158 billion market cap and $62.6 billion TTM revenue, focuses on innovative medicines in oncology, vaccines, and rare diseases. Recent market activity shows resilience, with shares up 13% YTD and 18% over one year to around $28. Sentiment has been bolstered by pipeline advancements, including positive Phase 3 Lyme vaccine data and breast cancer trial results showing 40% risk reduction. Despite COVID product declines, non-COVID operational growth of 6% underscores core portfolio strength, with 2026 revenue guidance at $59.5-62.5 billion reflecting disciplined cost management and R&D investments exceeding $10 billion.
PRAX Overview and Recent Performance
Praxis Precision Medicines (PRAX), a clinical-stage biopharma with $7.7 billion market cap and minimal revenue, targets CNS disorders via neuronal excitation-inhibition therapies like ulixacaltamide for essential tremor. Shares trade near $276, with 6% YTD but explosive 615% one-year gains amid volatility. Recent developments include FDA acceptance and priority review of relutrigine NDA for SCN2A/SCN8A developmental epileptic encephalopathies (DEEs), with PDUFA in September 2026, plus $926 million cash extending runway to 2028. Multiple Phase 3 readouts expected in 2026 fuel sentiment, though pre-revenue status amplifies risks from trial outcomes.
ZTS Overview and Recent Performance
Zoetis (ZTS), the leading animal health firm with ~$51 billion market cap and $9.5 billion 2025 revenue, provides medicines for companion and livestock animals. Shares hover at $116, up 7% YTD but down 28% over one year. Recent weakness stems from safety concerns over osteoarthritis drug Librela, reduced vet visits, and competition, prompting guidance cuts. Q4 2025 revenue grew 3% to $2.4 billion, with livestock strength offsetting companion animal softness; 2026 outlook projects $9.8-10 billion revenue (3-5% organic growth). Acquisitions like Neogen's genomics bolster long-term positioning.
Trending AI Robots
Tickeron's Trending AI Robots page showcases top-performing AI trading bots curated for current market conditions from hundreds available—specifically, 25 trending bots selected from a total of 351 AI agents that trade thousands of tickers across stocks, ETFs, and crypto. These bots vary in styles (technical/fundamental), timeframes (e.g., 60min, 15min, 5min), and volatility tolerances (low to high), with recent performers posting annualized returns up to 171% over 30 days and win rates like 100% on select strategies. No bots are noted for PFE, PRAX, or ZTS, but the platform's AI analyzes all for optimal fits. Explore Trending AI Robots to leverage these tools for healthcare sector opportunities.
Head-to-Head Comparison
PFE's diversified pharma model (~$63B revenue) contrasts PRAX's high-risk biotech focus (pre-revenue, NDA-stage) and ZTS's niche animal health (~$9.5B revenue). Growth drivers: PRAX hinges on CNS catalysts like dual NDAs; PFE on oncology/vaccines; ZTS on livestock/parasitics amid companion slowdowns. Recent momentum favors PRAX (615% 1Y) over PFE (18%) and lagging ZTS (-28%). Risks: PRAX's binary trials vs. PFE/LOEs (loss of exclusivity) and ZTS/Librela issues. Valuations sensitive to execution: PFE attractive on scale, PRAX premium for upside, ZTS defensive but pressured. Sentiment tilts biotech amid healthcare rotation.
Tickeron AI Verdict
Tickeron's AI currently favors PRAX for superior trend consistency, with multiple 2026 catalysts like relutrigine PDUFA and Phase 3 readouts positioning it ahead in relative momentum versus PFE's steady but slower growth and ZTS's headwinds. Probabilistic upside appears highest for PRAX amid biotech enthusiasm, though volatility warrants caution.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
PFE’s FA Score shows that 1 FA rating(s) are green whilePRAX’s FA Score has 0 green FA rating(s), and ZTS’s FA Score reflects 2 green FA rating(s).
- PFE’s FA Score: 1 green, 4 red.
- PRAX’s FA Score: 0 green, 5 red.
- ZTS’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
PFE’s TA Score shows that 3 TA indicator(s) are bullish while PRAX’s TA Score has 4 bullish TA indicator(s), and ZTS’s TA Score reflects 4 bullish TA indicator(s).
- PFE’s TA Score: 3 bullish, 5 bearish.
- PRAX’s TA Score: 4 bullish, 5 bearish.
- ZTS’s TA Score: 4 bullish, 6 bearish.
Price Growth
PFE (@Pharmaceuticals: Major) experienced а -4.94% price change this week, while PRAX (@Biotechnology) price change was +1.86% , and ZTS (@Pharmaceuticals: Generic) price fluctuated -0.07% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.86%. For the same industry, the average monthly price growth was -2.62%, and the average quarterly price growth was +6.54%.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.04%. For the same industry, the average monthly price growth was -3.95%, and the average quarterly price growth was +5.21%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +3.18%. For the same industry, the average monthly price growth was +3.88%, and the average quarterly price growth was -0.58%.
Reported Earning Dates
PFE is expected to report earnings on May 05, 2026.
PRAX is expected to report earnings on May 13, 2026.
ZTS is expected to report earnings on May 07, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.86% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (+1.04% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Generic (+3.18% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
| PFE | PRAX | ZTS | |
| Capitalization | 153B | 8.81B | 49.6B |
| EBITDA | 16.8B | -326.06M | 4.07B |
| Gain YTD | 9.923 | 7.261 | -5.926 |
| P/E Ratio | 19.79 | N/A | 19.58 |
| Revenue | 62.6B | 0 | 9.47B |
| Total Cash | 13.6B | 599M | 2.31B |
| Total Debt | 64B | 110K | 9.24B |
PFE | ZTS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 73 | 7 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 33 Fair valued | 29 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 73 | 16 | |
PRICE GROWTH RATING 1..100 | 35 | 61 | |
P/E GROWTH RATING 1..100 | 34 | 86 | |
SEASONALITY SCORE 1..100 | 32 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ZTS's Valuation (29) in the Pharmaceuticals Generic industry is in the same range as PFE (33) in the Pharmaceuticals Major industry. This means that ZTS’s stock grew similarly to PFE’s over the last 12 months.
ZTS's Profit vs Risk Rating (100) in the Pharmaceuticals Generic industry is in the same range as PFE (100) in the Pharmaceuticals Major industry. This means that ZTS’s stock grew similarly to PFE’s over the last 12 months.
ZTS's SMR Rating (16) in the Pharmaceuticals Generic industry is somewhat better than the same rating for PFE (73) in the Pharmaceuticals Major industry. This means that ZTS’s stock grew somewhat faster than PFE’s over the last 12 months.
PFE's Price Growth Rating (35) in the Pharmaceuticals Major industry is in the same range as ZTS (61) in the Pharmaceuticals Generic industry. This means that PFE’s stock grew similarly to ZTS’s over the last 12 months.
PFE's P/E Growth Rating (34) in the Pharmaceuticals Major industry is somewhat better than the same rating for ZTS (86) in the Pharmaceuticals Generic industry. This means that PFE’s stock grew somewhat faster than ZTS’s over the last 12 months.
| PFE | PRAX | ZTS | |
|---|---|---|---|
| RSI ODDS (%) | N/A | N/A | 1 day ago 55% |
| Stochastic ODDS (%) | 1 day ago 61% | 1 day ago 82% | 1 day ago 68% |
| Momentum ODDS (%) | 1 day ago 54% | 1 day ago 90% | 1 day ago 54% |
| MACD ODDS (%) | 1 day ago 55% | 1 day ago 90% | 1 day ago 65% |
| TrendWeek ODDS (%) | 1 day ago 58% | 1 day ago 86% | 1 day ago 61% |
| TrendMonth ODDS (%) | 1 day ago 54% | 1 day ago 88% | 1 day ago 63% |
| Advances ODDS (%) | 11 days ago 56% | 18 days ago 85% | 3 days ago 52% |
| Declines ODDS (%) | 1 day ago 57% | 5 days ago 84% | 16 days ago 58% |
| BollingerBands ODDS (%) | 1 day ago 54% | 1 day ago 90% | 1 day ago 62% |
| Aroon ODDS (%) | 1 day ago 51% | 1 day ago 87% | 1 day ago 65% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| GMEU | 10.30 | 0.33 | +3.31% |
| T-Rex 2X Long GME Daily Target ETF | |||
| IBIG | 26.27 | N/A | -0.01% |
| iShares iBonds Oct 2030 Term Tips ETF | |||
| IJS | 122.88 | -0.37 | -0.30% |
| iShares S&P Small-Cap 600 Value ETF | |||
| HYBL | 27.85 | -0.09 | -0.32% |
| State Street® Blackstone High Income ETF | |||
| AAPX | 26.70 | -0.11 | -0.41% |
| T-Rex 2X Long Apple Daily Target ETF | |||
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been closely correlated with MRK. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if PFE jumps, then MRK could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | -1.10% | ||
| MRK - PFE | 67% Closely correlated | -1.03% | ||
| BMY - PFE | 66% Closely correlated | -1.43% | ||
| BIIB - PFE | 64% Loosely correlated | -2.34% | ||
| AMGN - PFE | 61% Loosely correlated | -1.29% | ||
| NVS - PFE | 57% Loosely correlated | -0.65% | ||
More | ||||
PRAX and
Correlation & Price change
A.I.dvisor indicates that over the last year, PRAX has been loosely correlated with BEAM. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if PRAX jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To PRAX | 1D Price Change % | ||
|---|---|---|---|---|
| PRAX | 100% | -1.28% | ||
| BEAM - PRAX | 40% Loosely correlated | +4.18% | ||
| BHVN - PRAX | 37% Loosely correlated | -2.34% | ||
| RAPP - PRAX | 35% Loosely correlated | -0.15% | ||
| VERU - PRAX | 35% Loosely correlated | -2.06% | ||
| RXRX - PRAX | 35% Loosely correlated | -0.91% | ||
More | ||||
ZTS and
Correlation & Price change
A.I.dvisor indicates that over the last year, ZTS has been loosely correlated with ELAN. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ZTS jumps, then ELAN could also see price increases.
| Ticker / NAME | Correlation To ZTS | 1D Price Change % | ||
|---|---|---|---|---|
| ZTS | 100% | -1.78% | ||
| ELAN - ZTS | 52% Loosely correlated | -1.41% | ||
| VTRS - ZTS | 44% Loosely correlated | -1.03% | ||
| PRGO - ZTS | 41% Loosely correlated | +2.45% | ||
| HLN - ZTS | 40% Loosely correlated | -0.40% | ||
| PAHC - ZTS | 39% Loosely correlated | -2.03% | ||
More | ||||